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ABSTRACT
Objective: The balance between coronary endothelial
dysfunction and repair is influenced by many protective
and deleterious factors circulating in the blood. We
studied the relationship between oxidised low-density
lipoprotein (oxLDL), circulating endothelial progenitor
cells (EPCs) and coronary endothelial function in
patients with stable coronary heart disease (CHD).
Methods: 33 patients with stable CHD were studied.
Plasma oxLDL was measured using ELISA, coronary
endothelial function was assessed using intracoronary
acetylcholine infusion and EPCs were quantified using
flow cytometry for CD34+/KDR+ cells.
Results: Plasma oxLDL correlated positively with the
number of EPCs in the blood (r=0.46, p=0.02). There
was a positive correlation between the number of
circulating EPCs and coronary endothelial function
(r=0.42, p=0.04). There was no significant correlation
between oxLDL and coronary endothelial function.
Conclusions: Plasma levels of oxLDL are associated
with increased circulating EPCs in the blood of patients
with CHD, which may reflect a host-repair response to
endothelial injury. Patients with stable CHD had a high
prevalence of coronary endothelial dysfunction, which
was associated with lower numbers of circulating
EPCs, suggesting a mechanistic link between
endothelial dysfunction and the pathogenesis of
atherosclerosis.
INTRODUCTION
Oxidised low-density lipoprotein (oxLDL)
injures the vascular endothelium, a key step
in the pathogenesis of atherosclerosis.1 An
important mechanism of endothelial repair
involves the mobilisation and homing of
bone marrow-derived endothelial progenitor
cells (EPCs) to sites of injury, repopulating
the artery with functional endothelial cells
(ECs). Circulating levels of EPCs in blood
are increased following many forms of endo-
thelial injury including ischaemia in experi-
mental animals2 and myocardial infarction in
humans,3 4 but there are conﬂicting data on
whether circulating EPC levels correspond to
the severity of coronary heart disease
(CHD).5 6 EPCs are more resistant than
mature ECs to the toxic effects of oxidative
stress due to greater expression of potent
antioxidant enzymes7 that allow EPCs to pro-
liferate and differentiate in areas of
increased oxidative stress, such as ischaemic
tissues. EPC mobilisation is known to be trig-
gered by several proinﬂammatory cytokines
and growth factors including granulocyte
macrophage-colony stimulating factor,
stromal cell-derived factor-1, matrix metallo-
proteinases, vascular endothelial growth
factor (VEGF) and erythropoetin.8 In labora-
tory studies, oxLDL is toxic to cultured
KEY QUESTIONS
What is already known about this subject?
▸ Endothelial progenitor cells (EPCs) are crucial
mediators of vascular repair following endothe-
lial injury and the number of circulating EPCs is
influenced by many factors, including myocar-
dial ischaemia and levels of proinflammatory
cytokines.
What does this study add?
▸ We found the number of circulating EPCs was
correlated with plasma oxidised low-density
lipoprotein (oxLDL) in patients with stable cor-
onary heart disease, most of whom were taking
statins and other cardioprotective medications.
The number of circulating EPCs also correlated
with a measure of coronary endothelial function.
How might this impact on clinical practice?
▸ Our study suggests a host-repair response to
oxLDL, demonstrated by an increase in circulat-
ing EPCs. Elevated levels of EPCs have the
potential to improve endothelial function. Our
data highlight the potential role of targeted mea-
sures to promote endothelial function which, in
turn, may improve cardiovascular health.
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EPCs,9–12 however, the in vivo relationship between
plasma oxLDL and the number of circulating EPCs in
the blood is not known. Lowering oxLDL in humans
pharmacologically has a heterogeneous effect on endo-
thelial dysfunction, with most coronary segments
showing enhancement of dilation to acetylcholine
(ACh), but other segments showing a reduction in dila-
tion.13 We hypothesised that elevated plasma oxLDL in
patients with stable CHD would result in an increase in
circulating EPCs and that this may have a positive effect
on endothelial function. The aim of this study was there-
fore to investigate the relationship between plasma
oxLDL and EPCs in patients with stable CHD and
whether circulating EPCs inﬂuence coronary endothelial
function. To our knowledge, this is the ﬁrst study to
investigate this relationship and our results provide evi-
dence that elevated oxidative stress may stimulate
mechanisms involved in endothelial repair, thereby
exerting an effect on endothelial function.
METHODS
Study population
This cross-sectional observational study was approved by
the West Glasgow ethics committee (05/S0709/
138-Coronary stent deployment, oxidative stress, endo-
thelial regeneration and risk of thrombosis) and the
investigation conformed with the principles outlined in
the Declaration of Helsinki. All individual data were col-
lected in a blinded fashion. All participants were pro-
vided with a Patient Information Sheet and gave
informed written consent. To be included in the study,
patients had to be over age 18 and scheduled to
undergo elective percutaneous coronary intervention
(PCI) to treat stable CHD. All patients had at least one
major epicardial coronary artery suitable for endothelial
function testing (<30% stenosis and at least 2.5 mm in
diameter). Patients were excluded if there was a history
of myocardial infarction (MI) within 3 months or if they
were unable to give informed consent. One hour before
PCI, venous blood was removed for immediate assay of
circulating EPCs and plasma was stored at −70°C for sub-
sequent oxLDL assay. Patients then underwent routine
cardiac catheterisation as planned with the additional
component of invasive coronary endothelial function
testing prior to PCI.
OxLDL assay
OxLDL was detected by the commercial Mercodia solid
two-site ELISA (Diagenics, Bletchley, UK). In this assay,
two monoclonal antibodies were directed against separ-
ate antigenic determinants on the oxidised apolipopro-
tein B molecule. Samples were snap-thawed at 37°C for
3 min. All samples were run in duplicate. The average
coefﬁcient of variation of the duplicates was 0.6%. The
lowest sample value was 36 IU, which was above the
lowest standard (10 IU). All samples were therefore
within the sensitivity of the assay.
EPC assay
EPC sample preparation involved 1 mL of EDTA anticoa-
gulated blood added to 100 µL of Fc receptor (FcR)
blocking reagent (Miltenyi Biotec) and incubated for
20 min at room temperature. FcR blocking reagent
stopped the non-speciﬁc binding of IgG, reducing the
background noise in the sample. Five tubes were then
prepared, numbered 1–5, with 20 µL of anti-VEGF
receptor-2 APC added to tubes 1,3,4,5 and 20 µL
IgG1-APC was added to tube 2. One hundred microlitres
of the blocked blood, containing the FcR blocking
reagent, was then added to each of the tubes (1–5). All
tubes were incubated for a further 30 min on ice and
protected from light. Twenty microlitres of 7--
amino-actinomycin D visibility dye was added to each
tube for the exclusion of non-viable cells. Twenty micro-
litres of CD45-FITC/CD34-PE antibody combination was
then added to tubes 2, 3, 4, 5, with 20 µL of
CD45-FITC/CTL-PE added to tube 1. These tubes were
incubated at room temperature for 20 min and pro-
tected from light. Essentially, tube 1 acted as a control
for CD34 using CD45-FITC/CTL-PE and tube 2 as a
control for KDR, by adding CD45-FITC/CD34-PE.
Diluted lysis buffer was made up by adding 400 µL 10×
buffer to 3.6 mL of water. After 20 min incubation,
500 µL of lysis buffer was added to each tube before a
further 10 min of incubation in the dark. Finally, 100 µL
of a ﬂuorosphere stem count reagent was added to each
tube to prepare the sample for ﬂuorescence-activated
cell sorting (FACS) acquisition.
EPCs were quantiﬁed by ﬂow cytometry using FACS
analysis to look for markers CD34 and KDR, thought to
deﬁne EPCs.14 Data were analysed using Cellquest Pro
Software (BD) which involved the use of analytical gates
to count the total number and subsets of circulating
cells. Samples were run until 250 000 events were
counted or 20 min had elapsed. Data were then stored
for future analysis where EPCs were quantiﬁed as ((the
number of CD34+KDR+) events)×(concentration of
ﬂuorospheres))/(total number of ﬂuorospheres) per μL
of whole blood.
Coronary endothelial function testing
All vasodilator medications were withheld for 24 h prior to
testing. Coronary endothelial function was measured by
the standard method of assessing the change in luminal
diameter, using quantitative coronary angiography (QCA),
in response to an intracoronary infusion of the
endothelium-dependent vasodilator, ACh. In healthy arter-
ies, ACh causes release of nitric oxide (NO) from ECs,
leading to vasodilation. In endothelial dysfunction, the
NO response is blunted and the direct muscarinic smooth
muscle response to ACh predominates, causing paradox-
ical vasoconstriction. Following baseline coronary angiog-
raphy, the optimal angiographic projection for the study
artery was selected, avoiding overlapping side-branches. A
3 French infusion catheter (Cook Medical, Limerick,
Ireland) was placed into the proximal portion of the
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artery to be studied via a standard 6 French guiding cath-
eter. After intracoronary infusion of 0.9% saline as a
control, endothelium-dependent vasomotion was assessed
by serial infusions of ACh (Miochol-E, Novartis) in the fol-
lowing order: 10−6, 10−5 and 10−4 M at a ﬂow rate of
2 mL/min for 2 min. Assuming a mean coronary artery
blood ﬂow of 50 mL/min, the ﬁnal blood concentration
for each ACh infusion was 4×10−8, 4×10−7 and 4×10−6 M,
which was appropriate for the assessment of vasomotor
responses (recommended range 10−8 to 10−5 M).15 At the
end of each infusion, coronary angiography was per-
formed with contrast medium (Omnipaque, GE
Healthcare) using identical projections, table height and
magniﬁcation. The ACh infusion was terminated if
signiﬁcant ischaemia or bradycardia were observed.
Endothelium-independent vasomotion was ﬁnally assessed
using an intracoronary bolus injection of 400 µg isosorbide
dinitrate. If required, a further dose of isosorbide dinitrate
was administered to fully reverse any latent effects of ACh,
ensuring maximal coronary artery vasodilation before a
ﬁnal angiogram was recorded.
Quantitative coronary angiography
Coronary angiograms were stored digitally at the Golden
Jubilee National Hospital, Glasgow for subsequent ana-
lysis. An automated edge-detection software system
(Centricity CA1000, GE Healthcare) was used to
measure the luminal diameter of the coronary artery
distal to the infusion catheter, at end diastole. The mean
percentage change in luminal diameter compared to
control in two distinct 5 mm segments was calculated for
each patient following each infusion and after ﬁnal
nitrate injection (each analysis segment consisted of ﬁve
separate measurements 1 mm apart). Each segment was
easily identiﬁable by anatomical landmarks (such as side
branches). Endothelial function was deﬁned by the vaso-
motor response (% change in luminal diameter) to the
highest tolerated ACh infusion, compared to control.
Negative changes in vessel diameter represent vasocon-
striction. One patient did not receive 10−4 M ACh due
to recurrent atrioventricular block. All other patients
received all three concentrations of ACh. All QCA ana-
lysis was performed by a single observer, blinded to all
other study results.
Statistical analysis
A sample size of 25 patients was estimated to provide
80% power to detect a relationship between the inde-
pendent and the dependent variables at a two-sided 0.05
signiﬁcance level, if the true change in the dependent
variable is 0.3 units per unit change in the independent
variable. This was based on the assumption that the SD
of the independent variable (oxLDL) is 0.3 and the SD
of the dependent variable (endothelial function) is
0.15.16 All data are expressed as mean±SEM unless
otherwise stated. Correlations were performed using the
Pearson correlation coefﬁcient. To check whether other
patient characteristics inﬂuenced the relationship
between EPCs and oxLDL, gender, hypertensive status
and hypercholesterolaemic status were each individually
added to the model. Coronary responses for each infu-
sion were compared using analysis of variance and post
hoc Dunnett’s test. Statistical analysis was performed
using the SPSS statistical software package V.14.0 for
Windows (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Study participants
In total, 33 patients consented to the study. The endo-
thelial function study was not performed in one patient
due to time constraints in the catheterisation laboratory
and in another patient due to myocardial ischaemia
related to deep engagement of the infusion catheter.
Results for oxLDL (2 patients) and EPCs (8 patients)
were not available for analysis due to machine break-
down or late sample arrival. The patient baseline
characteristics are shown in table 1. Individual patient
data of plasma oxLDL concentration, EPC count and
endothelial function are shown in table 2. All patients
were receiving oral aspirin and clopidogrel therapy
along with standard pharmacotherapy for CHD, includ-
ing a high prevalence of statins.
Table 1 Baseline characteristics of patients
Baseline characteristics of
patients
Prevalence
(n=33)
Age, mean±SD (years) 62.4±8.36
Clinical characteristics, n (%)
Male 25 (75.8)
Female 8 (24.2)
Hypertension 17 (51.5)
Hypercholesterolaemia 23 (69.7)
Diabetes mellitus 3 (9.1)
Current smoker 4 (12.1)
Positive family history for CHD 16 (48.5)
Single vessel disease 26 (78.8)
Previous MI 9 (27.3)
Previous stroke 1 (3.03)
Preserved LV function 32 (97.0)
Heart failure 0 (0.0)
Previous PCI or CABG 3 (9.1)
Drug treatment, n (%)
Aspirin 33 (100.0)
Clopidogrel 33 (100.0)
ACE inhibitor 17 (51.5)
Angiotensin receptor blocker 4 (12.1)
β-blocker 29 (87.9)
Calcium channel blocker 13 (39.4)
Diuretic 16 (48.5)
Nitrate 16 (48.5)
Nicorandil 6 (18.2)
Statin 30 (90.9)
CHD, coronary heart disease; PCI, percutaneous coronary
intervention; MI, myocardial infarction; LV, left ventricular; CABG,
coronary artery bypass graft.
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Coronary endothelial function
The mean vessel response for each ACh infusion and
isosorbide dinitrate injection are shown in ﬁgure 1. The
mean response to incremental concentrations of ACh
was progressive vasoconstriction, which was signiﬁcant at
the highest concentration (1.36±1.48%, −4.74±1.68%
and −12.27±2.74% for 10−6, 10−5 and 10−4 M ACh,
respectively, p<0.001 for 10−4 M ACh vs control). The
mean response to isosorbide dinitrate was 9.94±2.15%,
p<0.001 versus control. There was good agreement
between the two segments analysed for each patient.
The mean difference in endothelial function between
the two segments analysed in each patient was 0.52 (SD
14.74) percentage points. Seven of 31 patients displayed
vasoconstriction in one segment and vasodilation in the
other segment. In such cases, the mean response was
calculated. There was a biphasic response to ACh in 5 of
31 patients, with a vasodilatory response at 10−6 M of
ACh (≥5% increase in vessel diameter) and vasoconstric-
tion at 10−4 M ACh (≥5% decrease in vessel diameter).
Adverse events
Transient atrioventricular block was relatively common
during ACh infusion (occurring in 5 patients), especially
during the highest concentration, but this was always
short-lived (less than 10 s) after the infusion was
stopped. One patient developed transient atrial ﬁbrilla-
tion. Clinical evidence of ischaemia was rare, occurring
in only two patients. Figure 2 shows an example of
severe vasoconstriction in the left anterior descending
coronary artery in one patient who developed marked
ischaemia during high-dose ACh infusion; this was
quickly reversed with intracoronary nitrate injection. No
serious or lasting complications were encountered.
Correlations
The mean plasma oxLDL concentration was 47.2 IU and
the mean number of circulating EPCs in venous blood
was 0.21±0.06 per µL. There was a signiﬁcant positive
correlation between oxLDL and the number of circulat-
ing EPCs (r=0.46, p=0.02). The individual data for these
results are displayed in ﬁgure 3A. Adding hypertensive
status, hypercholesterolaemic status or gender individu-
ally to the model did not affect the relationship between
oxLDL and EPCs (data not shown). Diabetes mellitus
and smoking were present in no greater than three
patients, so these variables were not included in the ana-
lysis due to insufﬁcient power to detect an effect. One
patient had a much greater value for EPCs and to
ensure the regression was not unduly inﬂuenced by this
value, a sensitivity analysis was conducted by was remov-
ing this data point from the model. Following this, the
Figure 1 Mean vasomotor response to serial acetylcholine
infusions and isosorbide dinitrate. There was significant
vasoconstriction during the highest acetylcholine
concentration whereas administration of isosorbide dinitrate
caused vasodilation. n=31; *p<0.001 vs control.
Table 2 Individual patient results for oxLDL, EPCs and
coronary response to ACh
Patient No oxLDL (IU)
EPCs
(µL blood)
% Change
in diameter
(10−4 M ACh)
1 36.34 0.2672 −1.6140
2 70.33 0.0142 −18.2796
3 49.39 0 −34.1583
4 100.89 0.3351 14.1741
5 82.65 0.3233 −0.2766
6 72.66 0.4110 −14.7591
7 65.92 1.1996 −2.1605
8 72.08 0.5567 3.3432
9 56.38 0.2376 −8.6903
10 56.06 ND −6.1734
11 44.22 0.4284 −1.6225
12 42.87 0.4909 −2.3068
13 38.77 0 −37.7922
14 53.55 0.2537 −47.2260
15 23.36 0.0480 −37.0728
16 42.52 ND −8.5830
17 20.01 ND −17.5202
18 36.22 0 −14.9939
19 41.86 ND −12.1033
20 34.64 0.0976 −19.6740
21 NS 0.0505 −26.7600
22 48.35 0.5088 3.7042
23 42.25 ND −3.9413
24 36.81 0 16.5367
25 29.26 0 −19.0864
26 29.33 0 ND
27 41.92 0.0788 −11.3369
28 41.01 0 −3.9623
29 41.73 0.0266 −14.1770
30 26.31 ND ND
31 33.99 ND −1.5818
32 NS ND −9.2091
33 50.65 0 −39.1786
ACh, acetylcholine; EPCs, endothelial progenitor cells; ND, not
determined; NS, no sample; oxLDL, oxidised low-density
lipoprotein.
4 Watt J, Kennedy S, Ahmed N, et al. Open Heart 2016;3:e000342. doi:10.1136/openhrt-2015-000342
Open Heart
group.bmj.com on February 26, 2016 - Published by http://openheart.bmj.com/Downloaded from 
correlation between oxLDL and EPCs remained signiﬁ-
cant (p=0.02). There was also a signiﬁcant positive cor-
relation between the number of circulating EPCs and
coronary endothelial function (r=0.42, p=0.04). This
data are shown in ﬁgure 3B. Thus, patients with fewer
circulating EPCs displayed more severe coronary endo-
thelial dysfunction. Age inversely correlated with circu-
lating EPC levels (r=−0.46, p=0.02). Given the
potentially confounding effect of statins with regard to
EPCs and endothelial function, an exploratory analysis
was performed excluding three patients not prescribed a
statin. After excluding these patients, the positive
correlation between oxLDL and the number of circulat-
ing EPCs (r=0.43, p=0.04) and EPCs and endothelial
function (r=0.53, p=0.01) remained signiﬁcant. There
was no signiﬁcant correlation between oxLDL and
coronary endothelial function (r=0.31, p=0.11).
Endothelium-independent vasodilation induced by iso-
sorbide dinitrate was not correlated with any parameter.
DISCUSSION
This study tested coronary endothelial function in
patients with stable CHD and assessed its relationship
with circulating levels of EPCs and oxLDL. The major
novel ﬁndings of this study were as follows: (1) There
was a high prevalence of coronary endothelial dysfunc-
tion in this patient population; (2) oxLDL correlated
positively with EPCs; (3) EPCs correlated positively with
coronary endothelial function.
OxLDL and EPCs
The mean EPC count in the study population is broadly
in agreement with previous studies.17 A novel ﬁnding
was that oxLDL measured in the peripheral blood of
patients with CHD was positively correlated with
circulating EPC numbers. This result was contrary to
much of the literature reporting in vitro toxicity of
oxLDL toward EPCs. Besides the diverse methods to
identify EPCs in the literature, our ﬁnding may be
explained by a number of issues. In previous studies,
EPC dysfunction occurred at 1–10 μg/mL oxLDL11 12
and EPC apoptosis (5–10%) was induced only by
25 μg/mL oxLDL or higher.9 10 18 Wang et al19 reported
a reduction in cultured EPCs (∼50%) at a concentration
of 100 μg/mL oxLDL. However, in contrast, low concen-
trations (5 µg/mL) of oxLDL were found to have a posi-
tive effect on EPC tube formation through activation of
endothelial nitric oxide synthase (eNOS).20 In our study,
the mean plasma oxLDL concentration of 47.2 IU was
equivalent to 14.1 μg/mL (personal communication
Figure 3 (A) Scatter plot of plasma oxLDL concentration
and the number of circulating EPCs (CD34+/KDR+ cells).
OxLDL was correlated with EPC numbers (n=24; r=0.46;
p<0.05). (B) Scatter plot of the number of circulating EPCs
(CD34+/KDR+ cells) and coronary endothelial function.
Endothelial function is represented by % change in vessel
diameter during acetylcholine, compared to control. EPC
numbers were correlated with endothelial function (n=24;
r=0.42; p<0.05). EPCs, endothelial progenitor cells; oxLDL,
oxidised low-density lipoprotein.
Figure 2 Angiographic example of severe coronary
endothelial dysfunction. Progressive vasoconstriction of the
left anterior descending artery after serial acetylcholine
infusions. Isosorbide dinitrate injection caused complete
reversal of vasoconstriction. LAD, left anterior descending.
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from manufacturer). Furthermore, studies that investi-
gated the protective effect of statins found that
oxLDL-induced EPC dysfunction and senescence were
profoundly inhibited by 1 μM atorvastatin, which may
occur via activation of Akt.11 12 Indeed, statin ‘reloading’
can be used to raise the numbers of circulating EPCs in
patients undergoing PCI.21 Thus, the relatively low con-
centration of oxLDL in the blood and liberal use of
statins in our contemporary CHD population may have
protected circulating EPCs against oxLDL-induced
damage. That circulating EPCs were actually increased
in those with higher oxLDL concentration is a novel
ﬁnding that merits further consideration and conﬁrma-
tory study. We postulate that this positive correlation may
be due to a host-repair response, induced by the dam-
aging effects of increased circulating oxLDL on the
vasculature; or that plasma oxLDL is a trigger (direct or
indirect) for the release and mobilisation of EPCs from
the bone marrow. OxLDL stimulates the release of
several proinﬂammatory chemokines in patients with
CHD22 and one or more of these factors may have been
responsible for increased numbers of EPCs in the circu-
lation. For instance, oxLDL markedly stimulates the
release of interleukin (IL)-8 and growth regulated
oncogene alpha (GRO-α) from peripheral blood mono-
nuclear cells and platelets in patients with CHD.22 These
family of IL-8/GRO-α chemokines have since been
shown to promote the homing of EPCs to areas of
ischaemic myocardium.23 The number of circulating
EPCs may also be increased in acute coronary syn-
dromes4 24 and severe forms of CHD,5 which are both
associated with elevated oxLDL in the blood.25 A recent
study has found rapid intracoronary recruitment of
EPCs in patients with ST elevation myocardial infarction,
likely to represent a reparative response.4
EPCs and endothelial function
We have shown that the number of circulating EPCs in
the peripheral blood of patients with stable CHD was
correlated with coronary endothelial function. Hill
et al26 previously showed in 45 individuals without cardio-
vascular disease that peripheral vascular function
(assessed by ﬂow-mediated brachial artery reactivity) was
correlated with the number of EC colony forming units
in culture, thought at the time to represent EPCs
derived from peripheral blood. It has since been estab-
lished that this widely cited study assessed an aspect of
endothelial biology that did not reﬂect the number of
actual EPCs present in the circulation.27 EPCs are widely
believed to originate from haematopoietic stem cells,
which are positive for CD34 (or the more immature
marker protein CD133) and the EC antigen, KDR.
These putative EPCs appear to make a valuable contri-
bution to vessel formation. Hence, the measurement of
CD34+/KDR+ cells is thought to be the most appropri-
ate way to deﬁne circulating EPCs,27 consistent with our
study. Werner et al28 reported a positive correlation
between EPCs and coronary endothelial function and
their ﬁnding has not, to the best of our knowledge,
been conﬁrmed since by others. This study in 90
patients with stable CHD measured the number of circu-
lating EPCs in peripheral blood using ﬂow cytometry to
quantify CD34+/KDR+ and CD133+ cells. The ability of
EPCs to produce endothelial colony forming units was
also measured. It was found using univariate analysis
that patients with low EPC number had the most
severely impaired coronary endothelial function and
CD34+/KDR+ cells were more strongly correlated with
endothelial function than CD133+ cells. The failure of
endothelial colony forming units to independently
predict endothelial function probably relates to their dis-
sociation with the number of circulating CD34+/KDR+
cells.27 By improving the capacity of the endothelium to
be repaired after vessel injury, an obvious link between
circulating EPC numbers and coronary endothelial func-
tion exists. The conﬁrmation herein and by Werner
et al28 that lower numbers of EPCs are associated with
impaired coronary endothelial function provides a
pathological basis for the ability of EPCs to predict car-
diovascular outcome.29
Limitations
The method to identify EPCs in this study using speciﬁc
haematopoietic and endothelial markers, CD34 and
KDR, is consistent with contemporary guidance,27 but
the most accurate way to quantify EPCs remains specula-
tive. It may have been useful to assess EPC function, as
this may have revealed a negative association with
plasma oxLDL levels and provided insights into endo-
thelial dysfunction present in patients with elevated oxi-
dative stress. We did not measure oxLDL antibodies
which may have provided an assessment of oxLDL for-
mation over a longer time period, however, the correl-
ation between these variables is not linear.30 Although,
vasodilator drugs were withheld for 24 h before assess-
ment of endothelial function, studies have shown that
calcium channel blockers31 and ACE inhibitors32 can
increase circulating EPCs. Thus, we cannot rule out the
possibility that variable uptake of non-statin cardiopro-
tective medications contributed to the correlations we
found in our relatively small study.
CONCLUSIONS
This observational study has conﬁrmed a high preva-
lence of coronary endothelial dysfunction in patients
with stable CHD. Plasma oxLDL correlated with the
number of circulating EPCs in the blood, possibly due
to the presence of a host-repair response and the pro-
tective effects of prescribed statins. Coronary endothelial
function in this population was correlated with the
number of circulating EPCs, which has been conﬁrmed
by one other group.28 Future studies should aim to
deﬁne the reasons for reduced numbers of EPCs in
cases of severe endothelial dysfunction and identify strat-
egies to prevent this decline.
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